文献速递胃肠外科围术期管理与 ERAS

围术期红细胞输注真的会恶化结肠癌肿瘤学结局吗?

Do packed red blood cell transfusions really worsen oncologic outcomes in colon cancer?
PubMed 文献 · Surgery · 2017-06-09

该回顾性队列纳入2004-2014年一家三级医疗中心接受原发性结肠癌切除术的1423例患者,其中305例(21.4%)在首次住院期间接受围术期浓缩红细胞输注。输注组总体死亡率更高(53.1% vs 30.9%,P < .001),但长期远处复发率和疾病特异性死亡率无显著差异,多变量Cox回归也未显示复发或疾病特异性死亡风险增加。

要点

  • 围术期红细胞输注与结肠癌术后总体死亡率升高相关,但与肿瘤复发无关。
  • 输注组与未输注组的长期远处复发率无显著差异(11.1% vs 13.9%,P = .25)。
  • 多变量Cox回归显示复发风险比0.83(95%CI 0.83-1.26,P = .38),无统计学差异。

核心结论

  • 围术期浓缩红细胞输注与结肠癌术后总体死亡率升高相关,但不支持其增加肿瘤复发或疾病特异性死亡的假设。

研究设计与样本

  • 回顾性队列研究,纳入2004-2014年一家三级医疗中心接受原发性结肠癌切除术的1423例患者,数据来自前瞻性维护的数据库。

主要发现

  • 305例(21.4%)接受围术期浓缩红细胞输注。
  • 输注组总体死亡率为53.1%,未输注组为30.9%(P < .001)。
  • 无基线转移患者中,长期远处复发率输注组11.1% vs 未输注组13.9%(P = .25)。
  • 疾病特异性死亡率输注组21.3% vs 未输注组17.3%(P = .104);无基线转移患者中为8.6% vs 8.9%(P = .89)。
  • 多变量Cox回归显示复发风险比0.83(95%CI 0.83-1.26,P = .38),疾病特异性死亡风险比1.12(95%CI 0.83-1.51,P = .47)。

临床怎么用

  • 围术期红细胞输注不应被视为结肠癌术后肿瘤复发的独立危险因素,临床决策应基于患者合并症和病情需要。

局限性

  • 本研究为单中心回顾性研究,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data from small retrospective studies have argued that perioperative packed red blood cell transfusions may increase the risk of developing metastatic recurrence in cancer patients. This study tests this assumption in a large cohort spanning a decade of operatively treated colon cancer patients. METHODS: All patients undergoing primary resection of a colon cancer at a tertiary care center between 2004-2014 (n = 1,423) were included in a retrospective review of a prospectively maintained data repository. Survival and disease-free survival were compared and also adjusted in multivariable Cox regression standardized for follow-up, American Society of Anesthesiologists score, age, sex, postoperative chemotherapy, baseline staging, and tumor grade. RESULTS: Of the 1,423 patients, 305 (21.4%) received a perioperative packed red blood cell transfusion during their index admission. During follow-up, overall mortality was greater in patients who received perioperative packed red blood cell (53.1% vs 30.9%; P < .001); however, there were no appreciable differences in rates of long-term distant recurrence (in patients without baseline metastasis 11.1% vs 13.9%; P = .25), or disease-specific mortality (21.3% vs 17.3%; P = .104; without baseline metastasis: 8.6% vs 8.9%; P = .89). Similarly, multivariable Cox regression showed no statistical difference in recurrence (hazard ratio: 0.83, 95% confidence interval, 0.83-1.26; P = .38) or disease-specific mortality (hazard ratio: 1.12, 95% confidence interval, 0.83-1.51; P = .47). CONCLUSION: Mortality rates were significantly greater in patients with perioperative packed red blood cell transfusions, a finding that is backed by a body of evidence that associates perioperative packed red blood cell transfusion with comorbidity and serious illness, but contrary to earlier evidence, findings in our cohort do not support a hypothesis that perioperative perioperative packed red blood cell transfusions have a detrimental effect on recurrence rates of operatively treated colon cancer patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Amri R, Dinaux AM, Leijssen LGJ, et al. Do packed red blood cell transfusions really worsen oncologic outcomes in colon cancer? Surgery. 2017. PMID: 28606725. doi:10.1016/j.surg.2017.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。